95 related articles for article (PubMed ID: 11754110)
1. Mutation rate of MAP2K4/MKK4 in breast carcinoma.
Su GH; Song JJ; Repasky EA; Schutte M; Kern SE
Hum Mutat; 2002 Jan; 19(1):81. PubMed ID: 11754110
[TBL] [Abstract][Full Text] [Related]
2. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene.
Su GH; Hilgers W; Shekher MC; Tang DJ; Yeo CJ; Hruban RH; Kern SE
Cancer Res; 1998 Jun; 58(11):2339-42. PubMed ID: 9622070
[TBL] [Abstract][Full Text] [Related]
3. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors.
Wang L; Pan Y; Dai JL
Oncogene; 2004 Aug; 23(35):5978-85. PubMed ID: 15184866
[TBL] [Abstract][Full Text] [Related]
4. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.
Teng DH; Perry WL; Hogan JK; Baumgard M; Bell R; Berry S; Davis T; Frank D; Frye C; Hattier T; Hu R; Jammulapati S; Janecki T; Leavitt A; Mitchell JT; Pero R; Sexton D; Schroeder M; Su PH; Swedlund B; Kyriakis JM; Avruch J; Bartel P; Wong AK; Tavtigian SV
Cancer Res; 1997 Oct; 57(19):4177-82. PubMed ID: 9331070
[TBL] [Abstract][Full Text] [Related]
5. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.
Yamada SD; Hickson JA; Hrobowski Y; Vander Griend DJ; Benson D; Montag A; Karrison T; Huo D; Rutgers J; Adams S; Rinker-Schaeffer CW
Cancer Res; 2002 Nov; 62(22):6717-23. PubMed ID: 12438272
[TBL] [Abstract][Full Text] [Related]
6. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
Kim HL; Vander Griend DJ; Yang X; Benson DA; Dubauskas Z; Yoshida BA; Chekmareva MA; Ichikawa Y; Sokoloff MH; Zhan P; Karrison T; Lin A; Stadler WM; Ichikawa T; Rubin MA; Rinker-Schaeffer CW
Cancer Res; 2001 Apr; 61(7):2833-7. PubMed ID: 11306453
[TBL] [Abstract][Full Text] [Related]
7. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression.
Ahn YH; Yang Y; Gibbons DL; Creighton CJ; Yang F; Wistuba II; Lin W; Thilaganathan N; Alvarez CA; Roybal J; Goldsmith EJ; Tournier C; Kurie JM
Mol Cell Biol; 2011 Nov; 31(21):4270-85. PubMed ID: 21896780
[TBL] [Abstract][Full Text] [Related]
8. Map2k4δ - identification and functional characterization of a novel Map2k4 splice variant.
Haeusgen W; Tueffers L; Herdegen T; Waetzig V
Biochim Biophys Acta; 2014 May; 1843(5):875-84. PubMed ID: 24487067
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.
Yoshida BA; Dubauskas Z; Chekmareva MA; Christiano TR; Stadler WM; Rinker-Schaeffer CW
Cancer Res; 1999 Nov; 59(21):5483-7. PubMed ID: 10554023
[TBL] [Abstract][Full Text] [Related]
10. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.
Hickson JA; Huo D; Vander Griend DJ; Lin A; Rinker-Schaeffer CW; Yamada SD
Cancer Res; 2006 Feb; 66(4):2264-70. PubMed ID: 16489030
[TBL] [Abstract][Full Text] [Related]
11. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor beta in the negative growth control of breast cancer cells.
Frey RS; Mulder KM
Cancer Res; 1997 Feb; 57(4):628-33. PubMed ID: 9044838
[TBL] [Abstract][Full Text] [Related]
12. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
[TBL] [Abstract][Full Text] [Related]
13. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course.
Xin W; Yun KJ; Ricci F; Zahurak M; Qiu W; Su GH; Yeo CJ; Hruban RH; Kern SE; Iacobuzio-Donahue CA
Clin Cancer Res; 2004 Dec; 10(24):8516-20. PubMed ID: 15623633
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
Davis SJ; Choong DY; Ramakrishna M; Ryland GL; Campbell IG; Gorringe KL
BMC Cancer; 2011 May; 11():173. PubMed ID: 21575258
[TBL] [Abstract][Full Text] [Related]
15. Disruption of MKK4 signaling reveals its tumor-suppressor role in embryonic stem cells.
Cazillis M; Bringuier AF; Delautier D; Buisine M; Bernuau D; Gespach C; Groyer A
Oncogene; 2004 Jun; 23(27):4735-44. PubMed ID: 15122334
[TBL] [Abstract][Full Text] [Related]
16. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss.
Cunningham SC; Gallmeier E; Hucl T; Dezentje DA; Calhoun ES; Falco G; Abdelmohsen K; Gorospe M; Kern SE
Cancer Res; 2006 Jun; 66(11):5560-4. PubMed ID: 16740690
[TBL] [Abstract][Full Text] [Related]
17. Analysis of cell growth inhibitory effects of catechin through MAPK in human breast cancer cell line T47D.
Deguchi H; Fujii T; Nakagawa S; Koga T; Shirouzu K
Int J Oncol; 2002 Dec; 21(6):1301-5. PubMed ID: 12429981
[TBL] [Abstract][Full Text] [Related]
18. Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers.
Cunningham SC; Gallmeier E; Hucl T; Dezentje DA; Abdelmohsen K; Gorospe M; Kern SE
Cell Cycle; 2006 May; 5(10):1090-3. PubMed ID: 16721048
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components.
Schuringa JJ; Jonk LJ; Dokter WH; Vellenga E; Kruijer W
Biochem J; 2000 Apr; 347 Pt 1(Pt 1):89-96. PubMed ID: 10727406
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.
Lotan TL; Lyon M; Huo D; Taxy JB; Brendler C; Foster BA; Stadler W; Rinker-Schaeffer CW
J Pathol; 2007 Aug; 212(4):386-94. PubMed ID: 17577251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
